tadalafil has been researched along with dutasteride in 7 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (dutasteride) | Trials (dutasteride) | Recent Studies (post-2010) (dutasteride) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 728 | 188 | 480 |
| Protein | Taxonomy | tadalafil (IC50) | dutasteride (IC50) |
|---|---|---|---|
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Homo sapiens (human) | 0.004 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Miura, K; Mizushima, A; Watanabe, D; Yamashita, A | 1 |
| Hashimoto, Y; Hatakeyama, S; Matsumoto, T; Narita, T; Ohyama, C; Yoneyama, T | 1 |
| Altinay, S; Gul, A; Kabasakal, L; Semercioz, A; Serefoglu, EC; Yavuz, A | 1 |
| Abe, N; Ishikawa, M; Kakizaki, H; Makino, S; Miyauchi, K; Wada, N | 1 |
| Fujimoto, K; Gotoh, D; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Torimoto, K | 1 |
1 review(s) available for tadalafil and dutasteride
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for tadalafil and dutasteride
| Article | Year |
|---|---|
Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
Topics: 5-alpha Reductase Inhibitors; Aged; Dose-Response Relationship, Drug; Drug Substitution; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Severity of Illness Index; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome | 2019 |
5 other study(ies) available for tadalafil and dutasteride
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride.
Topics: Drug Therapy, Combination; Dutasteride; Erectile Dysfunction; Humans; Japan; Male; Prostatic Hyperplasia; Quality of Life; Retrospective Studies; Tadalafil; Treatment Outcome | 2020 |
Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment.
Topics: Animals; Dutasteride; Male; Muscle, Smooth; Nitric Oxide Synthase; Penis; Rats; Rats, Sprague-Dawley; Tadalafil | 2020 |
Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome | 2022 |
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urinary Bladder, Overactive | 2022 |